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Abstract
Background: Norovirus (NoV) is a leading cause of sporadic cases and outbreaks of acute gastroenteritis (AGE).
Increased NoV activity was observed in Beijing, China during winter 2014–2015; therefore, we examined the
epidemiological patterns and genetic characteristics of NoV in the sporadic cases and outbreaks.
Methods: The weekly number of infectious diarrhea cases reported by all hospitals in Beijing was analyzed through
the China information system for disease control and prevention. Fecal specimens were collected from the outbreaks
and outpatients with AGE, and GI and GII NoVs were detected using real time reverse transcription polymerase chain
reaction. The partial capsid genes and RNA-dependent RNA polymerase (RdRp) genes of NoV were both amplified and
sequenced, and genotyping and phylogenetic analyses were performed.
Results: Between December 2014 and March 2015, the number of infectious diarrhea cases in Beijing (10,626 cases)
increased by 35.6 % over that of the previous year (7835 cases), and the detection rate of NoV (29.8 %, 191/640) among
outpatients with AGE was significantly higher than in the previous year (12.9 %, 79/613) (χ2 = 53.252, P < 0.001). Between
November 2014 and March 2015, 35 outbreaks of AGE were reported in Beijing, and NoVs were detected in 33 outbreaks,
all of which belonged to the GII genogroup. NoVs were sequenced and genotyped in 22 outbreaks, among which 20
were caused by a novel GII.17 strain. Among outpatients with AGE, this novel GII.17 strain was first detected in an
outpatient in August 2014, and it replaced GII.4 Sydney_2012 as the predominant variant between December 2014
and March 2015. A phylogenetic analysis of the capsid genes and RdRp genes revealed that this novel GII.17 strain was
distinct from previously identified GII variants, and it was recently designated as GII.P17_GII.17. This variant was further
clustered into two sub-groups, named GII.17_2012 and GII.17_2014. During winter 2014–2015, GII.17_2014 caused the
majority of AGE outbreaks in China and Japan.
Conclusions: During winter 2014–2015, a novel NoV GII.17 variant replaced the GII.4 variant Sydney 2012 as the
predominant strain in Beijing, China and caused increased NoV activity.
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Background
Norovirus (NoV) is the most common cause of epidemic
and sporadic cases of acute gastroenteritis (AGE) world-
wide [1]. In the United States, a single suspected or con-
firmed etiology was implicated in 2819 AGE outbreaks
during 2009 and 2010, and NoV was responsible for 1908
(68 %) outbreaks [2]. A systematic review of studies pub-
lished between January 1, 2008 and March 8, 2014, esti-
mated that global NoV prevalence in cases of AGE in
community, outpatient, and inpatient settings was 24 %
(95 % CI 18–30), 20 % (95 % CI 16–24), and 17 % (95 % CI
15–19), respectively [3].
The infectious dose for NoV is extremely low, with an
estimated median infectious dose of 18 viruses [4]. NoV
illness, which generally has an incubation of 24–48 h, is
characterized by the acute onset of nausea, vomiting,
abdominal cramps, and diarrhea, and these symptoms
usually resolve in 2–3 days [5, 6]. NoV is mainly spread
by oral–fecal contact through the ingestion of contami-
nated food or water or through direct contact with con-
taminated environmental surfaces or infected persons,
but exposure to NoVs in air or in aerosolized vomitus
has also been linked with infection [7].
NoV is a single-stranded, positive sense, RNA virus. Its
genome ranges from 7.3 to 7.5 kb and is organized into
three open reading frames (ORFs): ORF1 encodes a large
polyprotein, which is cleaved into at least six mature non-
structural proteins, including RNA-dependent RNA poly-
merase (RdRp); ORF2 and ORF3 encode the major (VP1)
and minor (VP2) capsid proteins. The VP1 protein con-
sists of three primary domains: the N-terminal domain
(N), the highly conserved shell domain (S), and the pro-
truding domain (P) that forms surface-exposed spikes.
The P domain is subdivided further into the hypervariable
P2 domain and the more conserved P1 domain; the pro-
truding P2 domain possesses several epitopes that are
involved in binding to the host cell [8]. NoV is classified
into six genogroups (I–VI), and at least 39 ORF2-based
genotypes have been described [7]. Only genogroups I, II,
and IV have been found to infect humans, and genogroup
II, genotype 4 (GII.4) strains are most commonly detected
worldwide [9].
Between December 2014 and March 2015, an increased
amount of infectious diarrhea cases was observed in
Beijing, China, and the monthly detection rates of NoV
among outpatients with AGE were higher than those of
the previous year. Therefore, we examined the epidemio-
logical patterns and genetic characteristics of NoV in spor-
adic cases and outbreaks.
Methods
AGE surveillance
The definition of infectious diarrhea used in this study
was diarrhea (i.e., three or more loose stools within a
24 h period) and/or vomiting as the presenting symp-
tom(s) of any disease caused by bacteria, viruses, fungi,
or parasites; cholera, dysentery, typhoid, or paratyphoid
were not included. The weekly numbers of infectious
diarrhea cases between January 2012 and March 2015,
which were reported by all hospitals in Beijing, were ob-
tained from the China information system for disease
control and prevention. These data was not freely avail-
able, and we had obtained the authorization from Beijing
Center for Disease Prevention and Control (CDC). Cases
of AGE were defined as patients who had diarrhea (as
defined above) and/or vomiting symptoms. The new
AGE outbreak surveillance was launched in April 2014,
and an outbreak was defined as an occurrence of three
or more cases of AGE within 3 days resulting from a
common exposure. The outbreaks of AGE were reported
by district-level CDCs, and fecal specimens were col-
lected and detected. NoV-positive specimens were sent
to the Beijing CDC, and 2–10 specimens per outbreak
were randomly selected for sequencing. The monitoring
system for sporadic AGE was launched in Beijing in
2011. Approximately 150 fecal specimens per month
were collected from outpatients with AGE at the enteric
disease clinics of 27 sentinel hospitals, which were lo-
cated in different geographical regions across Beijing.
The informed consent was obtained from the patients or
their guardians for the stool samples.
Viral RNA extraction
Viral RNA was extracted from 140 μL of a 10 % fecal sus-
pension in phosphate-buffered saline using the QIAamp
Viral RNA Mini Kit (QIAGEN, Hilden, Germany) accord-
ing to the manufacturer’s protocol. Extracted RNA was
stored at −20 °C until further use.
NoV detection
GI and GII genogroup NoVs were detected using a Super-
Script III Platinum® One-Step qRT-PCR Kit (Invitrogen,
Carlsbad, CA, USA) with primers and probes as described
previously [10].
Reverse transcription polymerase chain reaction (RT-PCR)
The QIAGEN One-Step RT-PCR Kit (QIAGEN, Hilden,
Germany) was used to amplify the genes of NoV in a 50-μL
reaction volume. RNase Inhibitor (Promega, Madison, WI,
USA) was added at a final concentration of 5–10 units/re-
action. The revised primers 289/290 (p290, nt4568–4590,
GATTACTCCAGGTGGGAYTCMAC; p289, nt4865–488
6, TGACGATTTCATCATCMCCRTA; positions are indi-
cated relative to the M87661 reference sequence) were used
to amplify the partial RdRp gene of NoV (319 bp) [11]. RT-
PCR was performed at 42 °C for 60 min and 95 °C for
15 min followed by 40 cycles of 94 °C for 30 s, 58 °C for
80 s, and 72 °C for 60 s; a final extension was run at 72 °C
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for 7 min. Primers G1SKF/G1SKR and G2SKF/G2SKR
were used to amplify the partial VP1 genes of GI and GII
NoVs, generating 330 bp and 344 bp PCR products [12].
RT-PCR was performed at 50 °C for 30 min and 95 °C for
15 min, followed by 40 cycles of 94 °C for 30 s, 55 °C for
30 s, and 72 °C for 60 s; a final extension was run at 72 °C
for 7 min. The ORF1/ORF2 junction region (1095 bp) was
amplified using primers 290 and G2SKR, and RT-PCR was
performed under the same reaction conditions for the VP1
gene of NoV. The PCR products were analyzed using a
QIAxcel Advanced Instrument with a QIAxcel DNA
Screening Kit (QIAGEN, Hilden, Germany).
DNA sequencing and phylogenetic analysis
PCR products were purified and sequenced directly on an
ABI 3730×l DNA Analyzer using a BigDye Terminator
v3.1 Cycle Sequencing Kit (ABI, Austin, TX, USA). All
sequences were prepared and aligned by BioEdit (version
7.0.9.0) with the Clustal W program. Genotypes were de-
termined by phylogenetic analyses with the Norovirus
Typing Tool (available at http://www.rivm.nl/mpf/noro-
virus/typingtool). The phylogenetic tree was constructed
using the maximum likelihood method with MEGA soft-
ware (version 6.06) and bootstrap analysis was performed
with 1000 replications. The sequences of the NoV strains
detected in this study were deposited in GenBank (acces-
sion numbers KR095171-KR095172, KT634313-KT6343
14, and KT633382-KT633396).
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS v13.0) software (SPSS
Inc., Chicago, IL, USA), and statistical significance was
set at P < 0.05.
Ethical statement
This study was approved by the Ethics Committee of the
Beijing CDC.
Results
Between December 2014 and March 2015, the number of
reported infectious diarrhea cases in Beijing (10,626 cases)
increased by 35.6 % over that of the previous year (7835
cases; Fig. 1). During this period, the overall detection rate
of NoV (29.8 %, 191/640) among outpatients with AGE
was significantly higher than the overall rate from the pre-
vious year (12.9 %, 79/613) (χ2 = 53.252, P < 0.001), and
the monthly detection rates of NoV among outpatients
were also higher than those of the previous year (Fig. 2).
Of the 191 NoV-positive specimens, 187 were identified
to be NoV GII, 3 belonged to NoV GI, and one was a
combined infection of NoV GI and GII. Of the 187 GII
NoVs, 109 were sequenced and 92 (84.4 %) belonged to a
novel GII.17 genotype. This novel GII.17 strain was first
detected in an outpatient with AGE in August 2014, and
it went on to replace GII.4 Sydney_2012 as the predomin-
ant variant between December 2014 and March 2015
(Fig. 3). The change in the detection rate of this GII.17
strain occurred concurrently with the increase in the
number of reported infectious diarrhea cases in Beijing.
Between November 2014 and March 2015, 35 out-
breaks of AGE were reported to the Beijing CDC, and
NoVs were detected in 33 of these outbreaks, all of
which belonged to the GII genogroup. The NoVs were
sequenced and genotyped in 22 outbreaks, of which 20
Fig. 1 The weekly number of infectious diarrhea cases in Beijing, China, reported through China information system for disease control and prevention,
between January 2012 and March 2015
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were caused by this novel GII.17 strain (4/5 in November
2014, 4/4 in December 2014, 5/6 in January 2015, 2/2 in
February 2015, and 5/5 in March 2015). Because the AGE
outbreak surveillance was launched quite recently, the
specimens from 11 outbreaks were not able to be obtained
for sequencing. The first outbreak caused by this strain
was reported at a university in October 2014, affecting
121 persons within 3 days, which was the only GII.17 out-
break reported that month.
A phylogenetic analysis of the NoV VP1 genes re-
vealed that the new GII.17 strains formed a single clus-
ter, sharing the highest identity with previous GII.17
strains (83.6–87.5 %) and with GII.13 strains (83.3–85.4 %)
(Fig. 4a). The new GII.17 strains have existed mainly in
eastern Asia since 2012, in contrast to previous GII.17
strains, which were prevalent worldwide up to 2011. The
RdRp genes of this variant were analyzed, and the genotype
could not be identified (Fig. 4b). The highest identity was
shared with GII.P3 (85.3–89.7 %) and GII.P13 strains
(84.9–88.6 %). The reference sequences of the GII.17 geno-
type were obtained from GenBank and were analyzed using
the Norovirus Typing Tool. The most common genotype
combination, based on VP1 and RdRp genes, was GII.P16_-
GII.17, and the other combinations included GII.P13_-
GII.17, GII.P4_GII.17, GII.Pe_GII.17, and GII.P3_GII.17.
Because this was the first orphan ORF1 sequence
Fig. 2 NoV detection rates by month between April 2013 and March 2015
Fig. 3 The monthly genotype distribution of GII NoVs among outpatients with acute gastroenteritis in Beijing, China, between August 2014 and
March 2015
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associated with GII.17, it was designated GII.P17_ GII.17 in
August 2014 [13]. The GII.P17_ GII.17 variant further clus-
tered into two sub-groups in the VP1 and RdRp genes,
named GII.17_2012 and GII.17_2014 according to the years
in which they were first reported. The dominant strain in
Beijing, Jiangsu, Guangdong, and Japan during winter
2014–2015 belonged to GII.17_2014.
Discussion
Over the past two decades, NoV GII.4 strains have been
responsible for the majority of both outbreaks and sporadic
cases of AGE [1]. GII.4 variants have emerged every 2–3
years, and these new variants replaced the old ones as the
predominant variant. The new variants have caused at least
six major pandemics: US 95/96 (1995–1996), Farmington
Hills (2002–2003), Hunter (2004–2005), Den-Haag_2006b
(2006–2007), New Orleans_2009 (2009–2010), and Syd-
ney_2012 (2012–2013) [14–19]. GII.3 was previously re-
ported to be the most common non-GII.4 genotype in
children (≤18 years of age) with AGE [20], and the other
genotypes, such as GII.6 [21] and GII.13 [22, 23], also had
higher detection rates in some regions in recent years, but
none of these non-GII.4 genotypes have ever replaced the
dominance of GII.4 genotypes.
Between December 2014 and March 2015, the detec-
tion rate of NoV among outpatients with AGE was sig-
nificantly higher than that for the previous year, and
GII.17_2014 was the dominant genotype during this
time. Bacterial pathogens were rarely detected during
these months, and there was no increase in the detection
rate of group A rotavirus. Additionally, enteric adenovi-
ruses and astroviruses were rare in Beijing during this
study period (data not shown). This evidence indicates
that GII.17_2014 caused the increase in the number of
infectious diarrhea cases in Beijing between December
2014 and March 2015.
GII.4 Sydney_2012 was first detected in August 2012
and replaced Den Haag 2006b as the predominant variant
in Beijing after September 2012. Between October and
December 2012, the monthly detection rates of NoV were
Fig. 4 Phylogenetic analysis based on partial VP1 genes (282 bp) (a) and RdRp genes (274 bp) (b) of the GII.17 NoVs. NoV strains detected in this
study were marked with the following symbols: ▲. The reference sequences were retrieved from GenBank. The trees were generated using the
maximum likelihood method, nucleotide substitution models Kimura 2-parameter (K2) + Gamma (G) + Invariant sites (I) was used for VP1 genes
and K2 + I for RdRp genes. Bootstrap values estimated with 1000 replicate data sets were indicated at each node. The scale bar indicated the
number of nucleotide substitutions per site
Gao et al. BMC Infectious Diseases  (2015) 15:574 Page 5 of 7
higher than those in the previous year, and the visits to
enteric clinics increased by 44.6 % compared with the
same period in the previous year [24]. Similar results were
also observed with GII.17_2014 in this study, which sug-
gests that this GII.17_2014 has the same epidemiological
fitness in Beijing as GII.4 Sydney_2012.
There are limited data about GII.17 NoV worldwide.
Earlier strains of GII.17 NoV were usually reported in
sporadic cases of AGE with a low detection rate, and it
was rarely linked with outbreaks [25–28]. Additionally,
GII.17 NoV was also detected in ground water, wastewa-
ter, and river water [29–32]. Most of the GII.17 NoV
sequences in GenBank only include partial VP1 genes,
and very few sequences cover ORF1 and ORF2. The first
report of GII.17_2012 in GenBank is from Japan in
February 2012; thereafter, such sequences in GenBank
are mainly from human specimens in East Asia (South
Korea, China Mainland, and Taiwan) and from surface
water in Kenya [33]. GII.17_2012 was also detected in
Beijing before August 2014, causing sporadic cases of
AGE. GII.17_2012 did not cause an increase in AGE
outbreaks, nor did it replace the predominant GII.4
strains in these regions.
GII.17_2014 emerged in Beijing in August 2014. It
replaced GII.4 Sydney_2012 as the predominant variant
among AGE outbreaks in November 2014 as well as
among sporadic cases of AGE after December 2014,
causing an increase in the NoV activity in Beijing. In
Jiangsu province, this strain was first found in October
2014, and it replaced GII.4 Sydney_2012 as the predomin-
ant variant in outbreaks after December 2014. GII.17_2004
dominated among sporadic cases since February 2015 in
Jiangsu province, and a corresponding increase in the NoV
detection rate among AGE cases was observed during this
time [34]. In Guangdong province, GII.17_2014 was first
detected in Guangzhou in November 2014, and it immedi-
ately replaced GII.4 Sydney_2012 as the predominant
variant from November 2014 through January 2015, caus-
ing an increase in the number of NoV outbreaks [35]. The
distribution of NoV genotypes among sporadic cases of
AGE in Guangdong was not available for inclusion. In
Japan, GII.17_2014 was a prevalent cause of NoV outbreaks
from December 2014 onwards, becoming the predominant
genotype in March 2015, but the total number of NoV out-
breaks during this season was lower than that of previous
years [13]. Based on the present data, it is probable that
GII.17_2014 first appeared in August 2014 in Beijing,
China, thereafter spread rapidly nationwide, and then ex-
panded to Japan.
Amino acid changes were observed in the P2 domains
of the VP1 protein between GII.17_2012 and GII.17_2014,
which might result in the antigenic drift or altered
receptor-binding properties [13, 34]. Additionally, differ-
ences were also found in the RdRp genes between
GII.17_2012 and GII.17_2014, which could potentially re-
sult in the increased replication efficiency of GII.17_2014.
The evolutionary history of GII.17_2014 remains un-
known, and additional sequences of complete genomes
from different times and regions should be analyzed.
GII.17_2014 NoV was termed Kawasaki 2014 after the
first near complete genome sequence (AB983218) submit-
ted to GenBank [36]. However, this strain actually belongs
to GII.17_2012 and was not the cause of the AGE out-
breaks in China and Japan, so a new and uniform name is
still needed.
Novel GII.17_2014 caused increased NoV activity in
China, but a similar situation was not observed in Japan,
even though this variant became the dominant genotype
there in March 2015. In the temperate Northern hemi-
sphere, NoV-associated AGE usually peaks during the
winter months (December–February) [37]. GII.17_2014
emerged in China 2–4 months before this peak, whereas
it appeared in Japan in December, when the previously
dominant strain may have hindered the spread of this new
variant. With the introduction of GII.17_2014 NoVs, an
increase in the number of NoV outbreaks or the replace-
ment of GII.4 Sydney 2012 viruses might happen outside
of Asia, so monitoring the trends in the geographical
spread and in the evolution of this variant is necessary.
We recommend that public health departments prepare
for a potential increase in NoV activity.
Conclusions
A novel NoV GII.17 variant emerged in Beijing in August
2014, which then replaced the GII.4 variant Sydney_2012
as the predominant strain during winter 2014–2015 and
caused an increase in NoV activity. A similar situation was
also observed in Jiangsu, Guangdong, and Japan. This is
the first time that a non-GII.4 genotype replaced the GII.4
variants as a predominant strain and caused increased
cases and outbreaks of AGE. This change provides new
challenges for the study of molecular evolution and the
development of NoV vaccines.
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